ICON Reveals Service Deal with Pfizer


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, revealed that it reached a three-year agreement with Pfizer Inc. (NYSE: PFE). However, the financial terms were not disclosed.According to ICON, the agreed terms enable Pfizer the right to extend the term for a maximum of an additional two years. The company added that the new agreement was built on the existing relationship, under which ICON offers global expertise in the planning, execution, management and conduct of clinical trials.The company's CEO, Ciaran Murray, stated: "The progression of our relationship with Pfizer is recognition of ICON's capabilities in supporting drug development efforts. We look forward to continuing our relationship with Pfizer to help advance its development pipeline and innovation in the drug development process."While ICLR closed with a loss of 1.63 percent, PFE ended Thursday with a gain of 0.20 percent.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsPress ReleasesGeneral